the cll12 trial of ibrutinib in early stage cll
Published 5 years ago • 284 plays • Length 2:57Download video MP4
Download video MP3
Similar videos
-
2:10
overview of cll12 trial of ibrutinib aiming to delay chemoimmunotherapy
-
2:51
genetic markers in patients with early-stage cll treated with ibrutinib: findings from cll12
-
1:37
cll12: ibrutinib
-
2:13
primary endpoint results of the cll12 trial
-
3:51
phase ib trial of ianalumab and ibrutinib in cll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
22:23
the bcr signaling pathway in cll
-
4:19
cll: what is 'watch & wait' and what can a patient do during this phase?
-
10:14
cll: the risk of richter’s transformation
-
3:14
understanding cll pathogenesis by assessing clonotypes
-
4:08
phase ib trial of ianalumab plus ibrutinib for cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:28
overview of resonate-2 clinical trial of ibrutinib in cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
0:49
overview of the cll2-big trial of ibrutinib and obinutuzumab
-
2:18
first-line ibrutinib and venetoclax in cll
-
4:43
phase ib trial of ianalumab plus ibrutinib for cll
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
1:37
causes & management of ibrutinib discontinuation in cll
-
3:29
how the management of cll is evolving